These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 16980962)

  • 1. Kinase activity of mutant LRRK2 mediates neuronal toxicity.
    Smith WW; Pei Z; Jiang H; Dawson VL; Dawson TM; Ross CA
    Nat Neurosci; 2006 Oct; 9(10):1231-3. PubMed ID: 16980962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
    Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
    Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
    Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
    Niu J; Yu M; Wang C; Xu Z
    J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
    Ito G; Okai T; Fujino G; Takeda K; Ichijo H; Katada T; Iwatsubo T
    Biochemistry; 2007 Feb; 46(5):1380-8. PubMed ID: 17260967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
    Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
    Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1.
    Greggio E; Lewis PA; van der Brug MP; Ahmad R; Kaganovich A; Ding J; Beilina A; Baker AK; Cookson MR
    J Neurochem; 2007 Jul; 102(1):93-102. PubMed ID: 17394548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucine-rich repeat kinase 2 associates with lipid rafts.
    Hatano T; Kubo S; Imai S; Maeda M; Ishikawa K; Mizuno Y; Hattori N
    Hum Mol Genet; 2007 Mar; 16(6):678-90. PubMed ID: 17341485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
    Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation.
    Greene ID; Mastaglia F; Meloni BP; West KA; Chieng J; Mitchell CJ; Gai WP; Boulos S
    J Neurosci Res; 2014 Apr; 92(4):506-16. PubMed ID: 24375786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.
    Li X; Moore DJ; Xiong Y; Dawson TM; Dawson VL
    J Biol Chem; 2010 Sep; 285(38):29569-76. PubMed ID: 20595391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin.
    Yang D; Li T; Liu Z; Arbez N; Yan J; Moran TH; Ross CA; Smith WW
    Neurobiol Dis; 2012 Sep; 47(3):385-92. PubMed ID: 22668778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
    Liu Z; West AB
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROCO kinase activity is controlled by internal GTPase function.
    Weiss B
    Sci Signal; 2008 Jun; 1(23):pe27. PubMed ID: 18544747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
    Skibinski G; Nakamura K; Cookson MR; Finkbeiner S
    J Neurosci; 2014 Jan; 34(2):418-33. PubMed ID: 24403142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and pathological characterization of Lrrk2.
    Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
    Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.